BAGI Research Limited

Leveraging our core expertise in computational chemistry, natural product chemistry, and high-throughput screening, BAGI has built a robust pipeline of proprietary small-molecule and botanical drug candidates. Derived from traditional Chinese medicine, our current programs target high-value therapeutic areas including rheumatoid arthritis, oncology, Parkinson’s disease, and drug-resistant influenza.

The company has an intellectual property portfolio of 45 granted patents.